Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Devarati Mitra Image

      Devarati Mitra, M.D., Ph.D.

      Department of Rad Onc Dept., Division of Radiation Oncology

      About Dr. Devarati Mitra

      Dr. Devarati Mitra is an Associate Professor in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center. Before joining the faculty, she received her MD and PhD at Harvard Medical School before completing her residency training at the Harvard Radiation Oncology Program.

      In her appointment to the Melanoma & Sarcoma Radiation Oncology section she specializes in the treatment of patients with melanoma, non-melanoma skin malignancies and bone or soft tissue sarcoma. Her clinical focus is on providing personalized patient care that brings the optimal radiation therapy approach to each patient’s unique cancer experience.

      Her research is focused on improving patient outcomes by optimizing radiotherapy in the context of rapidly evolving systemic therapy options while developing strategies to mitigate radiation-associated toxicities. She is the Primary Investigator of several clinical trials and has received research funding from multiple extramural sources including the National Institutes of Health (NIH), Melanoma Research Foundation (MRF) and American Society for Clinical Oncology (ASCO).

      Read More

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Voluntary Clinical Assistant Professor, The University of Houston College of Medicine, Houston, TX

      Dual/Joint/Adjunct Appointment

      Associate Professor, Radiation Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Voluntary Clinical Assistant Professor, The University of Houston College of Medicine, Houston, TX

      Education & Training

      Degree-Granting Education

      2014Harvard Medical School, Boston, Massachusetts, US, MD
      2012Harvard University, Boston, Massachusetts, US, Ph.D. in Biology & Biomedical Sciences
      2006Stanford University, Stanford, California, US, BS in Biological Sciences

      Postgraduate Training

      2015-2019Clinical Residency, Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts
      2014-2015Clinical Internship, Internal Medicine, Brigham & Women's Hospital, Boston, Massachusetts

      Licenses & Certifications

      2023Alabama Board of Medical Examiners
      2022Georgia Composite Medical Board
      2022Mississippi State Board of Medical Licensure
      2022Tennessee Board of Medical Examiners
      2022Arizona Medical Board
      2022Louisiana Medical Board
      2022Oklahoma State Board of Medical Licensure & Supervision
      2021Florida Board of Medicine
      2021American Board of Radiology
      2019Texas Medical License

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025

      Administrative Appointments/Responsibilities

      Mel/ Sarc Section Research Director, Radiation Oncology Clinical Research Council, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

      Associate Director of Medical Student Education, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present

      Other Professional Positions

      Associate Faculty Member, The University of Texas MD Anderson Cancer Center UT Health Houston Graduate School of Biomedical Sciences, Houston, TX, 2023 - Present

      Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, 2023 - Present

      Residency Education Case Conference Coordinator, Harvard Radiation Oncology Program, Cambridge, MA, 2018 - 2019

      Medical Student Education Coordinator, Harvard Radiation Oncology Program, Cambridge, MA, 2018 - 2019

      Non-Resident Tutor, Harvard University, Cambridge, MA, 2014 - 2018

      Teaching Assistant, Patient- Doctor 2, Harvard Medical School, Cambridge, MA, 2013 - 2014

      Teaching Assistant, Translational Pharmacology, Harvard Medical School, Cambridge, MA, 2011 - 2011

      Doctoral Student Teaching Assistant, Molecular Basis of Disease, Harvard Medical School, Cambridge, MA, 2009 - 2011

      Doctoral Student Teaching Assistant, Molecular Cell Biology, Harvard Medical School, Cambridge, MA, 2009 - 2011

      Undergraduate Alumni Interviewer, Stanford University, Stanford, CA, 2008 - Present

      Resident Tutor, Harvard University, Cambridge, MA, 2008 - 2014

      Intramural Institutional Committee Activities

      Member, Skin Management- Radiation Therapy Algorithm Working Group, The University of Texas MD Anderson Cancer Center, 2026 - 2026

      Member, MIM Adoption Working Group, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Co-Director, Melanoma Conference (MelCo), The University of Texas MD Anderson Cancer Center, 2025 - Present

      Reviewer, IRG Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Member, Melanoma Surgical Oncology New Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Disease Site Leader, Clinical Trials Prioritization Review (CTPR), The University of Texas MD Anderson Cancer Center, 2024 - Present

      Member, Melanoma Medical Oncology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025

      Member, NCCN Melanoma: Cutaneous Guidelines Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Melanoma Panel Member, Melanoma Multidisciplinary Network Conference, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Radiation Oncology Lead, Cutaneous Melanoma Algorithm Review Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, MCC International Planning Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024

      Member, Advanced Radiation Oncology Fellowship Interview Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, The Art and Science of Managing the New Melanoma Landscape Planning Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2022

      Chair, Faculty & Non-Faculty Seed Award Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2021

      Member, Joint Madrid MD Anderson Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

      Member, Sarcoma Multidisciplinary Planning Conference, The University of Texas MD Anderson Cancer Center, 2021 - 2023

      Member, Melanoma CME Conference Planning Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2021

      Co-chair, Non-melanoma Skin Cancer MD Anderson CME Conference, The University of Texas MD Anderson Cancer Center, 2021 - 2021

      Member, MD Anderson Research Foundations Pilot Testing, The University of Texas MD Anderson Cancer Center, 2021 - 2021

      Chair, ROSI Boot Walk Faculty and Non-faculty Seed Awards Committee, The University of Texas MD Anderson Cancer Center, 2021

      Melanoma/Sarcoma Section Liaison, RayStation Electron Planning Transition Team, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Committee Member, ROSI Non Faculty Seed Award Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2020

      Melanoma/Sarcoma Representative, Radiation Oncology Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Team Member, Radiation Oncology Covid Recovery Workstream – Virtual Care, The University of Texas MD Anderson Cancer Center, 2020 - 2020

      Extramural Institutional Committee Activities

      Reviewer, ESTRO Guideline Review Board, European Society for Radiotherapy and Oncology (ESTRO), 2026 - Present

      Member, Delphi Panel, Dana Farber Brigham Cancer Center/ Brigham and Women's Falkner Hospital, 2025 - Present

      Member, NRG FLASH Group, NRG Oncology, 2024 - Present

      Member, MRF Mucosal Melanoma Translational Working Group, Melanoma Research Foundation, 2023 - Present

      Editorial Activities

      Editor, PLOS One, 2018 - Present

      Honors & Awards

      2025OncoPitch 2025, The University of Texas MD Anderson Cancer center
      2024Andrew Sabin Family Fellow, The University of Texas MD Anderson Cancer Center
      2023RSNA Scholar Award, Radiological Society of North America
      2023Gilbert Fletcher Rising Stars Award, The University of Texas MD Anderson Cancer Center
      2018 - 2019ASCO Young Investigator Award, American Society of Clinical Oncology
      2018Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology
      2018Conquer Cancer Foundation Merit Award, Clinical Immuno-Oncology Symposium
      2018William Shipley Research Award, Massachusetts General Hospital
      2017 - 2018ASTRO Resident Seed Grant, American Society of Radiation Oncology
      2012 - 2014F30 Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship, National Institute of Environmental Health Sciences
      2011AACR Conference on Frontiers in Basic Cancer Research, American Association for Cancer Research
      2006Goldwater Scholarship, Barry Goldwater Scholarship and Excellence in Education Program
      2006Graduated Summa Cum Laude in Biological Sciences, Stanford University
      2006Phi Beta Kappa National Honor Society, Phi Beta Kappa National Honor Society
      2005Goldwater Scholarship, Barry Goldwater Scholarship and Excellence in Education Program
      2002National Merit Scholarship, National Merit Scholarship Corporation
      2002National AP Scholar, The College Board
      2002United States Marine Corps Scholastic Excellence Award, United States Marine Corps
      2002Maryland Distinguished Scholar, Maryland

      Professional Memberships

      NRG Oncology

      2023 - Present

      Big Owl/ Little Owl Program

      2021 - Present

      American Society of Clinical Oncology

      2017 - Present

      American Board of Radiology

      2015 - Present

      American Society for Radiation Oncology

      2014 - Present

      Massachusetts Medical Society

      2014 - 2019

      American Association for Cancer Research

      2011 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2026. Challenges with MSK Radiation Oncology. Invited. The Image Guided Cancer Therapy (IGCT) T32 Seminar. Houston, Texas, US.
      2. 2026. Cutaneous Tumors: MCC/ Melanoma/ SCC/BCC. Invited. NERO 2026. Houston, Texas, US.
      3. 2026. Therapy Concepts in Mel/Sarc. Invited. The Radiation Oncology and Radiation Therapy Education Series. Houston, Texas, US.
      4. 2025. PPPO Chart Rounds. Invited. Houston, Texas, US.
      5. 2024. Mel Sarc. Invited. Therapy Education Series. Houston, Texas, US.
      6. 2024. A radiation oncologist's foray into evaluation the role of the radiotherapy in the contemporary therapeutic era. Invited. Melanoma Research Seminar. Houston, Texas, US.
      7. 2024. The Role of Radiation Therapy in the Contemporary Management of Head and Neck Melanoma. Invited. Head and Neck - Plastic Reconstructive Surgery Melanoma Conference. Virtual, US.
      8. 2023. High Grade Sarcoma. Invited. Houston, TX, US.
      9. 2023. Mechanisms and Rationale of Systemic Treatments for Cancer. Invited. Houston, TX, US.
      10. 2022. Identification of IO-TOX Features Through Utilization of Circulome Analysis. Conference. Immunotoxicities Retreat. Houston, TX, US.
      11. 2022. Localized and Regional Melanoma Case Discussion. Conference. Art and Science of Managing the New Melanoma Landscape Conference. Houston, TX, US.
      12. 2021. Proton Therapy for Abdominopelvic Sarcomas. Conference. Houston, TX, US.
      13. 2020. Stage IV Disease. Conference. Houston, TX, US.
      14. 2020. Complex Cases of Multidisciplinary Sarcoma Management. Conference. Complex Cases of Multidisciplinary Sarcoma Management. Houston, TX, US.
      15. 2020. Melanoma Socratic. Conference. Houston, TX, US.
      16. 2019. Complex Cases of Multidisciplinary Melanoma Management. Conference. Houston, TX, US.

      Regional Presentations

      1. 2021. The Evolving Role of Radiotherapy in Melanoma Management. Invited. Cancer Network Melanoma Retreat. Virtual, TX, US.

      National Presentations

      1. 2025. Updates in Management for Melanoma. Invited. NASBS 34th Annual Meeting. New Orleans, LA, US.
      2. 2024. Sarcoma 2- Advancing Treatment Frontiers in Cutaneous Malignancies and Sarcoma. Invited. ASTRO 66th Annual Meeting. Washington DC, US.
      3. 2024. Contemporary FLASH-RT to its Clinical Translation- A Pathway to Bring Electron FLASH to Clinical Standard of Care. Invited. ASTRO 66TH Annual Meeting. Washington DC, US.
      4. 2024. New Technology Panel - Flash RT Updates. Invited. ASTRO 66th Annual Meeting. Washington DC, US.
      5. 2024. Sinonasal melanoma patterns of care and outcomes in the contemporary therapeutic era: a high-volume single institution experience. Invited. Multidisciplinary Head and Neck Cancers Symposium 2024. Phoenix, AZ, US.
      6. 2023. Adjuvant Radiation Therapy Improves Local Control in the Treatment of Adnexal Carcinoma. Invited. ASTRO 65th Annual Meeting. San Diego, CA, US.
      7. 2022. Anatomic Variability in Patterns of Care for Locoregional Merkel Cell Carcinoma (MCC) Management at a Large Referral Center. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      8. 2022. Gynecologic Melanoma: A 25-Year Institutional Experience. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      9. 2022. Outcomes after Definitive Treatment for Cutaneous Angiosarcomas of the Face and Scalp: Re-Evaluating the Role of Combined Modality Treatment. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      10. 2022. Prospective Single-Arm Trial of Preoperative 42.75 Gy in 15 Fractions for Soft Tissue Sarcoma of Extremity/Trunk. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      11. 2022. Stereotactic Ablative Radiation Therapy for Sarcoma Lung Metastases: Indications for Treatment and Patterns of Failure. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      12. 2022. The Role of Radiation in Melanoma in the Era of Immunotherapy and Targeted Therapies. Invited. ASTRO 2022 Annual Meeting. San Antonio, TX, US.
      13. 2021. Updates in Locoregional Skin Cancer Management. Invited. 63rd ASTRO Annual Meeting. Virtual, US.
      14. 2021. Patterns of Recurrence in Patients with Sentinel Lymph Node (SLN) Positive Melanoma in the Post-Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Era. Invited. Patterns of Recurrence in Patients with Sentinel Lymph Node (SLN) Positive Melanoma in the Post-Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Era, US.
      15. 2014. Vaginal cuff brachytherapy after external beam radiation is not associated with a dose-related increase in late toxicities. Invited. American Brachytherapy Society Annual Meeting. San Diego, CA, US.
      16. 2011. Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model. Invited. Society for Melanoma Research Annual Meeting. Tampa, FL, US.
      17. 2011. Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model. Invited. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA, US.

      International Presentations

      1. 2026. Lightening Debate 2: Standard vs. Shorter Course Radiation Therapy. Invited. The 4th Annual International Merkel Cell Carcinoma Symposium (MCC4). Boston, US.
      2. 2025. The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis. Poster. Society for Melanoma Research (SMR) 22nd International Congress. Amsterdam, NL.
      3. 2023. Hypofractionated Flash Radiation Treatment Reduces Skin and Soft Tissue Toxicity in a Murine Model. Invited. Flash Radiotherapy & Particle Therapy (FRPT) Annual Meeting. Toronto, CA.

      Formal Peers

      1. 2024. Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma. Virtual, US.
      2. 2023. MD Anderson Network Retreat’s Multidisciplinary Care Discussion Panel. Visiting. Virtual, US.
      3. 2023. Exploring Controversies in Management of Cutaneous Malignant Melanoma of the Head and Neck. Visiting. Virtual, US.
      4. 2023. Introduction to Clinical Oncology/ Radiation Oncology. Visiting. Houston, TX, US.
      5. 2023. The Evolving Role of Radiotherapy in Melanoma Management. Visiting. Jacksonville, FL, US.
      6. 2022. Melanoma/Cutaneous Multidisciplinary Presentation. Invited. Gilbert, AZ, US.
      7. 2021. Melanoma Lecture for Clinical Oncology Residents from the Cancer Diseases Hospital in Lusaka, Zambia. Visiting, US.
      8. 2021. Lunch and Learn Faculty Seminar. Invited. Houston, TX, US.
      9. 2020. Non-Melanoma Skin Cancer. Visiting. Houston, TX, US.
      10. 2019. Malignant Melanoma. Visiting. Houston, TX, US.
      Read More
      Less

      Selected Publications

      Peer-Reviewed Articles

      1. Sellers BT, Chaudhry A, Mitra D, Learned K, Sagiv O. Radiation Therapy and Nivolumab with Relatlimab-rmbw Achieved a Complete Response in Metastatic Cutaneous Melanoma to the Orbit. Ophthalmic Plast Reconstr Surg 42(5):e215-e219, 2026. e-Pub 2026. PMID: 41528958.
      2. Devireddy A, Yi Y, Nordlund KN, Lin R, Salem A, Yang NX, Keatts S, Jerez O, Farooqi A, Bishop AJ, Ashleigh Guadagnolo B, Nagarajan P, Weiser R, Fisher SB, Goepfert R, Ross MI, Amaria RN, Glitza Oliva IC, Yoder AK, Mitra D. ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with Microsatellitosis. Ann Surg Oncol 33(8):7481-7482, 2026. e-Pub 2026. PMID: 42223772.
      3. Devireddy A, Yi Y, Nordlund KN, Lin R, Salem A, Yang NX, Keatts S, Jerez O, Farooqi A, Bishop AJ, Guadagnolo BA, Nagarajan P, Weiser R, Fisher SB, Goepfert R, Ross MI, Amaria RN, Oliva ICG, Yoder AK, Mitra D. The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis. Ann Surg Oncol 33(8):7461-7470, 2026. e-Pub 2026. PMID: 42189441.
      4. Kassamali B, Schoenfeld JD, Sethi R, Bakst RL, Barker CA, Bhatt AA, Bradford CR, Bunch PM, Carr DR, Carucci JA, Chandra S, Chen M, Connolly KL, Demer AM, Doonan B, Emerick K, Friedman BJ, Gali LL, Galloway TJ, Geiger JL, Guenette JP, Kelly HR, Khushalani NI, Kohen L, Koyfman S, Kumar SS, Learned KO, Leitenberger JJ, Lilley EJ, Lukens JN, Medina T, Mitra D, Ozog D, Pashtan I, Patel VA, Pham N, Powers MC, Srivastava D, Swiecicki PL, Taylor CS, Witek ME, Wysong A, Zander D, Silk AW, Jambusaria-Pahlajani A, Ruiz ES. Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma. JAMA Dermatol, 2026. e-Pub 2026. PMID: 42418212.
      5. Amouzegar A, Wu X, Long JP, Chen GW, Wong JW, Prabhakaran S, Little L, Gumbs C, Bota N, Malke J, Simon J, Zhang J, Nagarajan P, Davies MA, Tawbi H, Amaria RN, Oliva ICG, Ikeguchi AP, Su S, Hanna EY, Weiser R, Bednarski B, Sims TT, Mitra D, Wargo J, Gershenwald JE, Scheet P, Yu Y, Huff C, Nelson KC, McQuade JL, Futreal PA. Germline variants in cancer susceptibility genes among patients with mucosal melanoma. NPJ Genom Med 11(1), 2026. e-Pub 2026. PMID: 42177185.
      6. McDonald J, De La Cruz D, Pinnix CC, Bronk JK, Hassanzadeh C, Holliday EB, Lee A, Mitchell MP, Mitra D, Perni S, Taku N, Gunther JR. Managing Radiation Therapy Treatment Delivery Challenges: Impact of an Interprofessional Educational Series for Radiation Therapists and Radiation Oncology Residents. J Cancer Educ, 2026. e-Pub 2026. PMID: 42068450.
      7. Salzillo T, Prajapati S, Yu ZH, Zhao Y, Lim TY, Wang H, Wang XA, Chen X, Kudchadker R, Lee B, Sobremonte A, Farooqi AS, Mitra D, Bishop A, Tang C, Yang J. Quantifying setup uncertainty between computed tomography guidance and magnetic resonance guidance in intramuscular metastases radiotherapy. J Appl Clin Med Phys 27(4):e70589, 2026. e-Pub 2026. PMID: 42003063.
      8. Konradsson E, Liu K, Baig S, Lin SJ, Lopez AH, Velasquez B, Mayor S, Samuel K, Viscarra T, Garrow K, Moore EJ, Norton W, Swain J, Li Z, Koong AC, Lin SH, Schuler E, Mitra D. Initial Evaluation of Feasibility and Cutaneous Toxicity of Electron FLASH Radiotherapy Using a Standard-of-Care Fractionation Scheme in a Porcine Skin Model. Cancers (Basel) 18(6), 2026. e-Pub 2026. PMID: 41899610.
      9. Yang NX, Rosamilia GL, Arifin AJ, Salem AF, Yoder AK, Keatts SA, Jerez O, Lin R, Bishop AJ, Farooqi AS, Weiser R, Ross MI, Mericli AF, Guadagnolo BA, Goepfert RP, Mitra D. Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiation Therapy for Primary Cutaneous Melanoma. Pract Radiat Oncol 16(2):e71-e77, 2026. e-Pub 2026. PMID: 41380909.
      10. Arifin AJ, Bishop AJ, Mitra D, Yoder A, Araujo DM, Haddad EFN, Ratan R, Livingston JA, Lewis VO, Lin PP, Moon BS, Keung EZ, Roland CL, Scally CP, Mericli AF, Guadagnolo BA, Farooqi AS. Outcomes Following Combined Modality Treatment to the Primary Site in Select Patients With Metastatic Soft Tissue Sarcoma. Pract Radiat Oncol 16(2):169-175, 2026. e-Pub 2026. PMID: 41579133.
      11. Yoder A, Netherton T, Wang X, Lim T, Wang C, Luo D, Wang C, Thrower S, Nguyen C, Lyu H, Scally C, Roland C, Mitra D, Bishop A, Farooqi A, Guadagnolo BA. The Impact of Radiation Dose to Bowel on the Risk of Developing Gastrointestinal Toxicities When Treating Abdominopelvic Soft-Tissue Sarcomas With Preoperative Radiation Therapy. Adv Radiat Oncol 11(2):101953, 2026. e-Pub 2026. PMID: 41492444.
      12. Mitra D, Bishop AJ, Guadagnolo BA. A Review of Melanoma. JAMA 335(3):280, 2026. e-Pub 2026. PMID: 41379434.
      13. Mandalapu AS, Yoder AK, Wang X, Mitra D, Bishop AJ, Guadagnolo BA, Farooqi AS. Excellent Response Following Palliative Radiation for Locally Advanced Epidemic/AIDS-Associated Kaposi Sarcoma of the Lower Extremity: A Case Report. Adv Radiat Oncol 10(8):101823, 2025. e-Pub 2025. PMID: 40686739.
      14. Salem AF, Chen MM, Williams MD, Swanson DM, McQuade JL, Amaria RN, Hanna EY, Bishop AJ, Farooqi AS, Guadagnolo BA, Su SY, Mitra D. Resectable Sinonasal Mucosal Melanoma in the Immunotherapy Era: Upfront Surgery vs. Neoadjuvant Therapy. Head Neck 47(7):1848-1856, 2025. e-Pub 2025. PMID: 39906003.
      15. Traweek RS, Zoghbi M, Lazcano R, Cope BM, Bishop AJ, Farooqi A, Mitra D, Yoder AK, Guadagnolo BA, Ingram DR, Wani K, Shamsutdinova D, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Ratan R, Livingston JA, Nakazawa MS, Araujo DM, Patel S, Ravi V, Conley AP, Zarzour MA, Somaiah N, Roland CL, Nassif Haddad EF. Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma. ESMO Open 10(7):105493, 2025. e-Pub 2025. PMID: 40561658.
      16. Liu K, Titt U, Esplen N, Connell L, Konradsson E, Yang M, Wang X, Takaoka T, Li Z, Koong AC, Mitra D, Mohan R, Loo BW, Lin SH, Schuler E. Discordance in Acute Gastrointestinal Toxicity between Synchrotron-Based Proton and Linac-based Electron Ultra-High Dose Rate Irradiation. Int J Radiat Oncol Biol Phys 122(2):491-501, 2025. e-Pub 2025. PMID: 39862897.
      17. Liu K, Waldrop T, Aguilar E, Mims N, Neill D, Delahoussaye A, Li Z, Swanson D, Lin SH, Koong AC, Taniguchi CM, Loo BW Jr, Mitra D, Schuler E. Redefining FLASH Radiation Therapy: The Impact of Mean Dose Rate and Dose Per Pulse in the Gastrointestinal Tract. Int J Radiat Oncol Biol Phys 121(4):1063-1076, 2025. e-Pub 2025. PMID: 39424078.
      18. Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Cancer 131(1):e35542, 2025. e-Pub 2025. PMID: 39192597.
      19. Torres MB, Leung CH, Zoghbi M, Lazcano R, Ingram D, Wani K, Keung EZ, Zarzour MA, Scally CP, Hunt KK, Conley A, Bishop AJ, Guadagnolo BA, Farooqi A, Mitra D, Yoder AK, Nakazawa MS, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar AJ, Roland CL, Somaiah N, Nassif Haddad EF. Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. Front Immunol 16:1567736, 2025. e-Pub 2025. PMID: 40370451.
      20. Keatts SA, Salem AF, Swanson DM, Farooqi AS, Bishop AJ, Amaria RN, McQuade JL, Glitza Oliva IC, Diab A, Weiser R, Fisher SB, Goepfert RP, Ross MI, Ashleigh Guadagnolo B, Mitra D. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma. Clin Transl Radiat Oncol 49:100856, 2024. e-Pub 2024. PMID: 39308633.
      21. Yoder AK, Farooqi A, Mitra D, Livingston JA, Araujo DM, Sturgis EM, Goepfert R, Bishop AJ, Guadagnolo BA. Outcomes for Patients With Head and Neck Sarcoma Treated Curatively With Radiation Therapy and Surgery. Pract Radiat Oncol 14(5):e373-e382, 2024. e-Pub 2024. PMID: 38851534.
      22. Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730715.
      23. Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys 118(4):971-978, 2024. e-Pub 2024. PMID: 37914142.
      24. Cass S, Cope B, Bishop AJ, Chiang YJ, Ashleigh Guadagnolo B, Farooqi A, Morrison W, Witt RG, Seervai RNH, Garden AS, Fuller CD, Goepfert RP, Ross M, Gershenwald JE, Wong M, Aung PP, Keung EZ, Mitra D. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol 188:109892, 2023. e-Pub 2023. PMID: 37659660.
      25. Chau BL, LaGuardia JS, Kim S, Zhang SC, Pletcher E, Sanford NN, Raldow AC, Singer L, Gong J, Padda SK, Kamrava M, Cohen T, Mitra D, Atkins KM. Association of Parental Status and Gender With Burden of Multidisciplinary Tumor Boards Among Oncology Physicians. JAMA Netw Open 6(10):e2340663, 2023. e-Pub 2023. PMID: 37906191.
      26. Yoder AK, Farooqi AS, Wernz C, Subramaniam A, Ravi V, Goepfert R, Sturgis EM, Mitra D, Bishop AJ, Guadagnolo BA. Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy. Head Neck 45(8):1943-1951, 2023. e-Pub 2023. PMID: 37272774.
      27. Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA. Gynecologic tract melanoma in the contemporary therapeutic era: high rates of local and distant disease progression. Gynecol Oncol 167(3):483-489, 2022. e-Pub 2022. PMID: 36229264.
      28. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
      29. Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
      30. Bishop AJ, Zheng J, Subramaniam A, Ghia AJ, Wang C, McGovern SL, Patel S, Guadagnolo BA, Mitra D, Farooqi A, Reardon MJ, Kim B, Guha-Thakurta N, Li J, Ravi V. Cardiac Angiosarcomas: Risk of Brain Metastasis and Hemorrhage Warrants Frequent Surveillance Imaging and Early Intervention. Am J Clin Oncol 45(6):258-263, 2022. e-Pub 2022. PMID: 35588225.
      31. Mitra D. Locoregional-Directed Therapy Is Still a Cornerstone of Anorectal Melanoma Management. Int J Radiat Oncol Biol Phys 112(5):1075, 2022. e-Pub 2022. PMID: 35286880.
      32. Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
      33. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo DM, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions. Adv Radiat Oncol 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
      34. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant Checkpoint Inhibitor Immunotherapy for Resectable Mucosal Melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
      35. Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
      36. Mitra D, Devlin PM, Buzurovic I, Thornton K, Lam AC, Raut CP, Baldini EH, Lam MB. Clinical outcomes following HDR surface applicator brachytherapy for angiosarcoma of the scalp and face. J Contemp Brachytherapy 2020:7615248, 2021. e-Pub 2021. PMID: 33897791.
      37. Mitra D, Devlin PM, Buzurovic I, Thornton K, Lam AC, Raut CP, Baldini EH, Lam MB. Clinical outcomes following high-dose-rate surface applicator brachytherapy for angiosarcoma of scalp and face. J Contemp Brachytherapy 13(2):172-178, 2021. e-Pub 2021. PMID: 33897791.
      38. Boyce-Fappiano D, Guadagnolo BA, Ratan R, Wang WL, Wagner MJ, Patel S, Livingston JA, Lin PP, Diao K, Mitra D, Farooqi A, Lazar AJ, Roland CL, Bishop AJ. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist 26(3):250-260, 2021. e-Pub 2021. PMID: 33289298.
      39. Lee G, Kim DW, Muralidhar V, Mitra D, Horick NK, Eyler CE, Hong TS, Drapek LC, Allen JN, Blaszkowsky LS, Giantonio B, Parikh AR, Ryan DP, Clark JW, Wo JY. Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal. Oncologist 25(12):1015-1022, 2020. e-Pub 2020. PMID: 32827337.
      40. Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J. Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. J Gastrointest Cancer 51(1):204-210, 2020. e-Pub 2020. PMID: 30980294.
      41. Mitra D, Pei Y, Buzurovic I, Devlin PM, Thornton K, Raut CP, Baldini EH, Lam MB. Angiosarcoma of the Scalp and Face: A Dosimetric Comparison of HDR Surface Applicator Brachytherapy and VMAT. Sarcoma 2020:7615248, 2020. e-Pub 2020. PMID: 32908445.
      42. Mitra, D, Chen, YH, Li, R, Hermann, G, Atkins, KM, Kozono, D, Baldini, EH, Aizer, A, Chukwueke, U, Mak, RH. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation Oncology 18:32-38, 2019. e-Pub 2019. PMID: 31341973.
      43. Mito JK, Mitra D, Barysauskas CM, Mariño-Enriquez A, Morgan EA, Fletcher CDM, Raut CP, Baldini EH, Doyle LA. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. Int J Radiat Oncol Biol Phys 104(2):425-435, 2019. e-Pub 2019. PMID: 30703514.
      44. Mitra D, Horick N, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AP, Allen JN, Ryan DP, Ting DT, Deshpande W, Wo JY. High IDO1 expression is associated with poor outcome in anal cancer patients treated with definitive chemoradiotherapy. Oncologist 24(6):e275-e283, 2019. e-Pub 2019. PMID: 30755500.
      45. Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of Her2 amplification in brain metastases from primary gastrointestinal malignancies. Oncologist 24(2):193-201, 2019. e-Pub 2019. PMID: 30373904.
      46. Fitarelli-Kiehl M, Ashtaputre R, Yu F, Supplee J, Paweletz C, Mitra D, Schoenfeld JD, Sarh P, Makrigiorgos GM. DNA end-repair and denaturation enhances digital droplet PCR-based analysis of small input liquid biopsies. Clin Chem 64(12):1762-1771, 2018. e-Pub 2018. PMID: 30274976.
      47. Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Pract Radiat Oncol 7(5):e291-e297, 2017. e-Pub 2017. PMID: 28462895.
      48. Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol 2(2):110-117, 2017. e-Pub 2017. PMID: 28740921.
      49. Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, Flaherty KT, Zheng B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 22(9):1056-61, 2016. e-Pub 2016. PMID: 27500726.
      50. Mitra D, Catalano PJ, Cimbak N, Damato AL, Muto MG, Viswanathan AN. The risk of lymphedema after postoperative radiation therapy in endometrial cancer. J Gynecol Oncol 27(1):e4, 2016. e-Pub 2016. PMID: 26463430.
      51. Mitra D, Nout R, Catalano PJ, Creutzberg C, Cimbak N, Lee L, Viswanathan AN. Rectal bleeding after radiation therapy for endometrial cancer. Radiother Oncol 115(2):240-5, 2015. e-Pub 2015. PMID: 26003340.
      52. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2(7):643-54, 2014. e-Pub 2014. PMID: 24903021.
      53. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7(3):645-53, 2014. e-Pub 2014. PMID: 24746818.
      54. Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, Brooks PJ, Fisher DE, Song H, Wang Y. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Research 41(13):6421-9, 2013. e-Pub 2013. PMID: 23658232.
      55. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research 19(5):1225-31, 2013. e-Pub 2013. PMID: 23307859.
      56. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-453, 2012. e-Pub 2012. PMID: 23123854.
      57. Levine CG, Mitra D, Sharma A, Smith CL, Hegde RS. The efficiency of protein compartmentalization into the secretory pathway. Molecular Biology of the Cell 16(1):279-91, 2005. e-Pub 2005. PMID: 15496459.
      58. Kim SJ, Mitra D, Salerno JR, Hegde RS. Signal sequences control gating of the protein translocation channel in a substrate-specific manner. Developmental Cell 2(2):207-217, 2002. e-Pub 2002. PMID: 11832246.

      Invited Articles

      1. Farooqi AS, Guadagnolo BA, Mitra D, Bishop AJ. Radiation Therapy for Retroperitoneal Sarcomas: A Strass-Ful Situation. Curr Oncol 30(1):598-609, 2023. e-Pub 2023. PMID: 36661696.
      2. Mitra D, Bishop A, Guadagnolo BA. Adjuvant nodal radiation therapy for melanoma in the era of immunotherapy. Int J Radiat Oncol Biol Phys 108(1):164-169, 2020. e-Pub 2020. PMID: 32544573.
      3. Farooqi A, Mitra D, Guadagnolo BA, Bishop AJ. The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma. Curr Oncol Rep 22(8):79, 2020. e-Pub 2020. PMID: 32602007.
      4. Mito JK, Mitra D, Doyle LA. Radiation-Associated Sarcomas: An Update on Clinical, Histologic, and Molecular Features. Surg Pathol Clin 12(1):139-48, 2019. e-Pub 2019. PMID: 30709440.
      5. Mitra D, Klopp AH, Viswanathan AN. Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer. Gynecol Oncol 140(1):167-75, 2016. e-Pub 2016. PMID: 26432041.
      6. Mitra D, Fisher DE. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 23(3):447-65, viii, 2009. e-Pub 2009. PMID: 19464596.

      Review Articles

      1. Bian MY, Stevens R, Mangla A, Mitra D, Zaorsky NG, Bordeaux JS, Rothermel LD. Advances in Therapeutic Melanoma Vaccines (2010-2025). Vaccines (Basel) 14(8), 2026. e-Pub 2026. PMID: 42646699.
      2. Kanala TS, Guadagnolo BA, Mitra D. The Role of Radiotherapy in the Management of Chest Wall Soft Tissue Sarcomas. Thorac Surg Clin 36(2):193-201, 2026. e-Pub 2026. PMID: 41927156.
      3. Arifin AJ, Mitra D. Radiation Therapy for Melanoma and Merkel Cell Carcinoma in the Contemporary Era. Surg Clin North Am 105(3):651-662, 2025. e-Pub 2025. PMID: 40412892.
      4. Sharafi CS, Guadagnolo BA, Nelson KC, Mitra D. Adjuvant Radiation Therapy in Desmoplastic Melanoma: A Scoping Review. Cancers (Basel) 16(22), 2024. e-Pub 2024. PMID: 39594829.

      Editorials

      1. Mitra D, Robinson KC, Fisher DE. Melanoma and viagra: an unexpected connection. Pigment Cell & Melanoma Research 24(1):16-18, 2011. PMID: 21290790.

      Abstracts

      1. Yoder AK, Salem Jr AFM, Nordlund K, Lin R, Shaitelman SF, Fuller CD, Lee A, Goodman CR, Guadagnolo BA, Bishop AJ, Farooqi A, Mitra D. Evaluating the Relationship of Baseline Skin Pigmentation Phenotype on the Evolution of Radiation Dermatitis. Int J Radiat Oncol Biol Phys 123(1):S64-S65, 2025. e-Pub 2025.
      2. Yang NX, Arifin AJ, Salem Jr AFM, Yoder AK, Keatts S, Jerez O, Lin R, Bishop AJ, Farooqi A, Goepfert RP, Weiser R, Ross MI, Guadagnolo BA, Mericli A, Mitra D. Surgical Graft and Flap Toxicity Following Hypofractionated Adjuvant Radiotherapy for Primary Cutaneous Melanoma. Int J Radiat Oncol Biol Phys 123(1):S71-S72, 2025. e-Pub 2025.
      3. Kanala TS, Yoder AK, Mitra D, Bishop AJ, Hooda Z, Araujo D, Ratan R, Somaiah N, Haddad Nassif EF, Mitchell KG, Rajaram R, Vaporciyan AA, Rice DC, Guadagnolo BA, Farooqi A. Outcomes for Patients with Localized Intrathoracic Soft Tissue Sarcomas Treated with Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys 123(1):e54- e55, 2025. e-Pub 2025.
      4. Nordlund K, Devireddy A, Lin R, Salem Jr AFM, Yang NX, Keatts S, Farooqi A, Bishop AJ, Guadagnolo BA, Weiser R, Fisher S, Goepfert RP, Ross MI, Amaria R, McQuade J, Glitza I, Yoder AK, Mitra D. The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma Microsatellitosis. Int J Radiat Oncol Biol Phys 123(1):S70, 2025. e-Pub 2025.
      5. Mitra D, Lin R, Farooqi A, Bishop AJ, Yoder AK, Pearlnath C, Kol S, Weiser R, Goepfert RP, Glitza I, Ross MI, Wong MK, Guadagnolo BA. A Prospective Single-Arm Trial of Postoperative 36 Gy in 10 Fractions for Merkel Cell Carcinoma. Int J Radiat Oncol Biol Phys 123(1):S70, 2025. e-Pub 2025.
      6. Arifin AJ, Bishop AJ, Mitra D, Dejka A, Haddad EN, Ratan R, Livingston AJ, Lewis V, Lin P, Moon B, Keung E, Roland C, Scally C, Mericli AF, Guadagnolo BA, Farooqi A. Addressing the Primary Site in Patients with Metastatic Soft Tissue Sarcoma: Is There a Role for a Combined Modality Treatment?. CTOS 29th Annual Meeting, 2024. e-Pub 2024.
      7. Salem AFM, Chen M, Williams MD, Swanson D, McQuade J, Amaria R, Farooqi A, Bishop AJ, Hanna EY, Guadagnolo BA, Su SY, Mitra D. Sinonasal Melanoma Outcomes After Neoadjuvant Immunotherapy. Int J Radiat Oncol Biol Phys 120(2):e483-e484, 2024. e-Pub 2024.
      8. Keatts S, Swanson A, Farooqi A, Bishop AJ, Amaria J, McQuade J, Glitza I, Diab A, Weiser R, Fisher S, Ross MI, Guadagnolo BA, Mitra D. Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma. Int J Radiat Oncol Biol Phys 120(2):S180-S181, 2024. e-Pub 2024.
      9. Arifin A, Bishop AJ, Mitra D, Araujo D, Haddad Nassif EF, Ratan R, Livingston JA, Lewis V, Lin P, Moon B, Keung E, Roland CL, Scally C, Guadagnolo BA, Farooqi A. Outcomes Following Combined Modality Treatment to the Primary Site in Patients with Metastatic Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 120(2):e426-e427, 2024. e-Pub 2024.
      10. Dudzinski SO, Farooqi A, Roy S, Bishop AJ, Swanson D, Nagarajan P, Amaria R, McQuade J, Weiser R, Fisher S, Ross MI, Guadagnolo BA, Mitra D. Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era. Int J Radiat Oncol Biol Phys 120(2):S180, 2024. e-Pub 2024.
      11. Arifin AJ, Jerez O, Keatts S, Salem AFM, Farooqi A, Bishop AJ, Yoder AK, Goepfert RP, Weiser R, Amaria R, McQuade J, Ross MI, Guadagnolo BA, Mitra D. Adjuvant Primary Site Radiation Therapy for Melanoma in the Immunotherapy Era. Int J Radiat Oncol Biol Phys 120(2):S179-S180, 2024. e-Pub 2024.
      12. Weiser R, McQuade J, Fisher S, Farooqi A, Amaria R, Guadagnolo BA, Bishop AJ, Patel SP, Diab A, Glitza IC, Bednarski BK, Ross MI, Mitra D. Combination of Radiotherapy and Immunotherapy or Patients Presenting with Locoregionally Advanced Anorectal Mucosal Melanoma. 2024 Society of Melanoma Research Congress, 2024. e-Pub 2024.
      13. Onuma A, Malik N, Cope B, Aung P, Morey R, Ingram D, Arunkumar V, Chiang Y, Mitra D, Witt R, Keung E. Assessing the 10% rule in Sentinel Lymph Nodes Biopsy in Merkel Cell Cancer. Ann Surg Oncol 31(Suppl 1):1-294, 2024. e-Pub 2024.
      14. Yoder A, Netherton T, Wang X, Lim TY, Wang H, Luo D, Wang C, Thrower S, Nguyen C, Mitra D, Bishop AJ, Farooqi A, Guadagnolo BA. The Impact of Tumor Location and Radiation Dose to Bowel on the Risk of Developing Gastrointestinal Toxicities when Treating Abdominopelvic Soft Tissue Sarcomas with Preoperative Radiation Therapy. CTOS 28th Annual Meeting, 2023. e-Pub 2023.
      15. Bishop AJ, Mitra D, Farooqi A, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher RL, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo BA. Long-term Disease Outcomes, Late Toxicity, and Function Following Hyprofractionated Preoperative Radiation Therapy for Patients with Soft Tissue Sarcomas: A HYPORT-STS Update. CTOS 28th Annual Meeting, 2023. e-Pub 2023.
      16. Torres MB, Leung CH, Keung E, Feng C, Beird H, Zarzour A, Scally C, Hunt K, Conley A, Bishop AJ, Guadagnolo BA, Farooqi A, Mitra D, Araujo D, Livingston A, Ratan R, Shreyaskumar P, Ravi V, Lazar A, Roland CL, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Experience. CTOS 28th Annual Meeting, 2023. e-Pub 2023.
      17. Gringrich AA, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally CP, Hunt KK, Torres KE, Roland CL, Rare Tumor Initiative Team, Patient Mosaic Team, Futreal A, Bishop AJ, Guadagnolo BA, Mitra D, Farooqi A, Araujo D, Zarzour MA, Livingston JA, Conley A, Shreyaskumar P, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif EF. Leiomyosarcoma Intratumoral Macrophage Infiltrates are Associated with Distinct Clinical and Genomic Presentations. CTOS 28th Annual Meeting, 2023. e-Pub 2023.
      18. Lillimoe H, Hunt K, Subramaniam A, Keung E, Roland C, Torres K, Lyu H, Scally C, Mitra D, Farooqi A, Bishop AJ, Guadagnolo BA, Ravi V. Primary Breast Angiosarcoma: Clinical and Pathological Features and Impact on Outcomes. CTOS 28th Annual Meeting, 2023. e-Pub 2023.
      19. Yoder AK, Farooqi A, Mitra D, Livingston JA, Araujo DM, Sturgis EM, Goepfert R, Bishop AJ, Guadagnolo BA. Outcomes for Patients with Head and Neck Sarcoma Treated Curatively with Radiation Therapy and Surgery 117(2):S149-S150, 2023. e-Pub 2023.
      20. Yoder AK, Netherton T, Wang XA, Lim TY, Wang H, Luo D, Wang C, Thrower SL, Farooqi A, Mitra D, Bishop AJ, Guadagnolo BA. Evaluating the Utility of Traditional Bowel Dose Constraints When Treating Abdominal and Pelvic Sarcomas with Preoperative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 117(2):E353-E354, 2023. e-Pub 2023.
      21. Mitra D, Gonzalez C, Swanson D, Bishop AJ, Farooqi A, Garden AS, Morrison WH, Goepfert RP, Esmaeli B, Ross MI, Wong MK, Ivan D, Guadagnolo BA. Adjuvant radiation therapy improves local control in the treatment of adnexal carcinoma. International Journal of Radiation Oncology, Biology, Physics 117(2):e325-e326, 2023. e-Pub 2023.
      22. Witt RG, Cope B, Seervai R, Chiang YJ, Fisher SB, Lucci A, Gershenwald JE, Wargo JA, Ross MI, Wong MK, Mitra D, Keung EZ. Neoadjuvant Systemic Therapy for Merkel Cell Carcinoma: A Tertiary Referral Center Experience 29(SUPPL 2):353-353, 2022. e-Pub 2022.
      23. Mitra D, Ologun G, Bishop AJ, Goepfert RP, Keung E, Amaria R, Wargo J, Guadagnolo BA. Nodal Recurrence Rates for Melanoma Patients With ≥1 mm Sentinel Lymph Node Involvement in the Era of Adjuvant Immunotherapy. International Journal of Radiation Oncology 108(3):E1, 2020. e-Pub 2020.
      24. Mitra D, Horick N, Brackett DG, Mouw K, Hornick JL, Hong TS, Ryan DP, Parikh AR, Clark JW, Deshpande V, Wo JY. The immune milieu of anal squamous cell carcinoma: IDO expression is correlated with poor outcome. Journal of Clinical Oncology 102(3), 2018. e-Pub 2018.
      25. Mitra D, Agarwal V, Chen YH, Baldini EH, Barbie DA, Chen AB, Glass B, Beck A, Herman G, Kozono DE, Schoenfeld JD, Mak RH. The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer treated with definitive intent. Journal of Clinical Oncology, 2018. e-Pub 2018.
      26. Mitra D, Mito J, Barysauskas CM, Raut CP, Doyle L, Baldini EH. Outcomes for Localized Radiation-Associated Sarcoma (RAS), Excluding Breast Angiosarcoma. International Journal of Radiation Oncology 99(2):755-6, 2017. e-Pub 2017.
      27. Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long term outcomes and toxicity of anal cancer patients treated per RTOG 0529. Adv Radiat Oncol 2(2):110-117, 2017. e-Pub 2017.
      28. Mitra D, Nout R, Creutzberg C, Lee L, Cimbak N, Viswanathan A. Does vaginal brachytherapy (VB) boost after external beam radiation therapy (EBRT) increase rectal bleeding? Comparing results of combined EBRT+VB to PORTEC-2 data for EBRT alone and VB alone. International Journal of Radiation Oncology 90(1), 2014. e-Pub 2014.
      29. D Mitra D, NC Cimbak NC, LJ Lee LJ, Viswanathan AA. Lymphedema: Is It Associated With Lymph-Node Involvement in Endometrial Cancer?. International Journal of Radiation Oncology 90(1):716-7, 2014. e-Pub 2014.
      30. Mitra D, Cimbak N, Damato AL, Lee L, Viswanathan A. Vaginal cuff brachytherapy after external beam radiation is not associated with a dose-related increase in late toxicities. Brachytherapy 13:77, 2014. e-Pub 2014.
      31. Mitra D, Shih HA, Oh KS, Brastianos PK, Wo JY, Curry WT, Clark JW, Parikh AR, Corcoran R, Ryan DP, Lennerz JK, Hong TS. Her2 positivity in brain metastases from gastrointestinal primary malignancies. Journal of Clinical Oncology 14(2), 2014. e-Pub 2014.
      32. Mitra D, Luo X, Morgan A, Wargo J, Fisher DE. Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model. American Association for Cancer Research 71(18), 2011. e-Pub 2011.

      Book Chapters

      1. Yoder AK, Mitra D, Guadagnolo BA. Non-Melanoma Skin Cancer. In: Pocket Radiation Oncology. 2nd. Wolters Kluwer, 345, 2024.
      2. Yoder AK, Mitra D, Guadagnolo BA. Melanoma. In: Pocket Radiation Oncology. 2nd. Wolters Kluwer, 2024.
      3. Yoder AK, Mitra D, Bishop AJ, Guadagnolo BA. Merkel Cell Carcinoma. In: Pocket Radiation Oncology. 2nd. Wolters Kluwer, 345, 2024.
      4. Avner M, McQuade J, Devarati M, Holder A, Davies M, Oliva Glitza IC. Malignant Melanoma. In: MD Anderson Manual of Medical Oncology.

      Letters to the Editor

      1. Mitra D, Guadagnolo BA. Nodal Radiotherapy for Anorectal Melanoma: Finding the Appropriate Time and Place. Int J Radiat Oncol Biol Phys 120: 929-930, 2024.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 16, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top